Literature DB >> 11206963

Deferoxamine pharmacokinetics.

J B Porter1.   

Abstract

Despite the clinical use of deferoxamine for more than a quarter of a century, pharmacokinetic studies are few and have not been performed explicitly in patients with sickle cell disorders. Early studies with Intravenous administration to healthy volunteers and patients with transfusional overload showed that although peak concentrations of deferoxamine were similar in both groups, concentrations of ferrioxamine were higher in the latter. In iron-overloaded patients with hereditary hemochromatosis, an intramuscular 10 mg/kg bolus of deferoxamine gave maximal plasma ferrioxamine concentrations exceeding those of deferoxamine, whereas in normal controls the reverse was the case. In more recent studies with homozygous beta-thalassemia, using continuous Intravenous deferoxamine infusion at 50 mg/kg/d, and initial elimination half-life of 0.28/h and steady-state concentration of 7 micromol/L were observed. In these studies, steady-state plasma levels of the predominant deferoxamine metabolite B were usually lower than those of unmetabolized deferoxamine. In a further intravenous infusion study, the proportion of plasma metabolites was higher in those thalassaemia patients with low serum ferritin levels relative to their current mean daily deferoxamine dose, suggesting that high metabolite levels may predict excessive desferrioxamine dosing. This hypothesis is supported by subcutaneous studies in which low doses of slow-release depot deferoxamine resulted in significantly lower proportions of plasma metabolites than with conventional 8-hour infusions at 40 mg/kg. Because serum ferritin is particularly unreliable as a marker of iron overload in sickle cell disorders, measurement of metabolites or the relative proportions of deferoxamine and ferrloxamine may help identify patients at risk of excessive dosing. Because iron overload is likely to become an increasing issue in patients with sickle cell disorders, studies of the pharmacokinetics and metabolism of deferoxamine in this patient group are needed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206963     DOI: 10.1016/s0037-1963(01)90061-7

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  22 in total

1.  Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Authors:  Patricia Evans; Reem Kayyali; Robert C Hider; John Eccleston; John B Porter
Journal:  Transl Res       Date:  2010-05-27       Impact factor: 7.012

Review 2.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

3.  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; John R T Vinson; Hua Yao; Neelam Bharti; James R Rocca
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

4.  Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.

Authors:  Xi-Ping Huang; Jake J Thiessen; Michael Spino; Douglas M Templeton
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

5.  Challenges of adherence and persistence with iron chelation therapy.

Authors:  John B Porter; Michael Evangeli; Amal El-Beshlawy
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

6.  Specific iron chelators determine the route of ferritin degradation.

Authors:  Ivana De Domenico; Diane McVey Ward; Jerry Kaplan
Journal:  Blood       Date:  2009-08-11       Impact factor: 22.113

7.  Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.

Authors:  Cassie Bennett; Farrah Mohammed; Anabel Álvarez-Ciara; Michelle A Nguyen; W Dalton Dietrich; Suhrud M Rajguru; Wolfgang J Streit; Abhishek Prasad
Journal:  Biomaterials       Date:  2018-10-18       Impact factor: 12.479

8.  Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration.

Authors:  Masanobu Okauchi; Ya Hua; Richard F Keep; Lewis B Morgenstern; Timothy Schallert; Guohua Xi
Journal:  Stroke       Date:  2009-12-31       Impact factor: 7.914

9.  Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers.

Authors:  Melanie Rodrigues; Clark A Bonham; Caterina P Minniti; Kalpna Gupta; Michael T Longaker; Geoffrey C Gurtner
Journal:  Adv Wound Care (New Rochelle)       Date:  2018-10-11       Impact factor: 4.730

10.  Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.

Authors:  Shahina Daar; Anil Pathare; Hanspeter Nick; Ulrike Kriemler-Krahn; Abdel Hmissi; Dany Habr; Ali Taher
Journal:  Eur J Haematol       Date:  2008-12-22       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.